Starling Oncology Stock (NASDAQ:STLN)
Previous Close
$6.18
52W Range
$2.32 - $7.13
50D Avg
$6.25
200D Avg
$4.48
Market Cap
$662.89M
Avg Vol (3M)
$1.49M
Beta
0.42
Div Yield
-
STLN Company Profile
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.